NEWSLETTER

Sign up to read weekly email newsletter
Asia Tech Times
Donate
Search
  • Home
  • Breaking News
  • Business
  • Finance
  • Medical
  • Political
Reading: Billionaire Mehta Brothers’ Gush To Purchase Risk In India’s JB Pharma In $1.4 Billion Offer
Share
Font ResizerAa
Asia Tech TimesAsia Tech Times
  • Finance
  • Technology
Search
  • Home
  • Categories
    • Finance
    • Technology
  • More Foxiz
    • Blog Index
    • Forums
    • Complaint
    • Sitemap
Follow US
Made by ThemeRuby using the Foxiz theme. Powered by WordPress
Breaking News

Billionaire Mehta Brothers’ Gush To Purchase Risk In India’s JB Pharma In $1.4 Billion Offer

By Asia Tech Times
Last updated: 06/07/2025
3 Min Read
Share
JB Pharma

JB Chemical Plant in Gujarat, western India.

Supplied by JB Chemicals

Gush medicine– Managed by Indian Billionaire Sibling Sudhir and Samir Mehta– Has actually accepted purchase risk in JB Chemicals and Pharmaceuticals in an offer of 11,910 crore (US$ 1.4 billion).

Gush Pharma will certainly purchase 46.4% of JB Pharma for Rs 1,600 per share and will certainly likewise purchase up to 2.8% of the shares from some workers at the very same cost. It will certainly after that make a deal to purchase 26% of the shares at Rs 1,639.18 each, hence paying a minor costs to the minority investors. According to the joint statement Launch on Sunday.

” This calculated uniformity even more reinforces our existence in the Indian pharmaceutical market and constructs a bigger international existence,” Samir Mehta, exec chairman of Gush Pharma, claimed in a declaration.

After the deal is finished, both firms will certainly combine with investors holding 100 shares of JB Pharma and obtain 51 Gush shares. These purchases are authorized by regulatory authorities.

The bargain enabled Gush Pharma to acquire a fast-growing pharmaceutical service in India. According to its internet site, JB Pharma was started in 1976 and creates a series of substance abuse in gastroenterology, high blood pressure, dermatology and diabetes mellitus. Since March 2025, the business (exports its items to over 40 nations consisting of the USA) climbed to Rs 6.6 crore.

” As we get in a brand-new phase with Gush Pharmaceuticals, we are positive that the mixed toughness of our company will certainly open extra possibilities to boost health care possibilities throughout the marketplace,” claimed Nikhil Chopra, Chief Executive Officer of JB Pharma.

According to the 100 wealthiest checklist launched by India Forbes Asia Last October. Much of their riches originates from Gush Pharma, the major business of the $4.9 billion (earnings) Gush Team. The 64-year-old business was started by the late daddy Uttambhai Nathalal Mehta, a previous sales person for Swiss pharmaceutical large Sandoz.

TAGGED:BillionBillionaireBrothersBuydealIndiasMehtapharmastakeTorrent

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Email Copy Link Print

SUBSCRIBE NOW

Subscribe to our newsletter to get our newest articles instantly!

HOT NEWS

United States, China Establish For Talks in Stockholm on Toll Truce Expansion

Leading financial authorities from the USA and China will certainly return to settlements on Monday…

28/07/2025

China’s CATL Really feels the Pinch of a Lithium Cost Downturn it Developed

Years of long-lasting decreases in lithium costs are currently beginning to take a toll on…

19/03/2025

OpenAI strategies Sora video clip generator combination right into ChatGPT

Sora was released in December 2024 as a standalone internet application, making it possible for…

19/03/2025

YOU MAY ALSO LIKE

Embattled Celebrity Considers $157 Million Cash Money Deal From United State Gambling enterprise Driver Bally’s

Celebrity Facility, run by Celebrity Home entertainment Team Ltd. at Celebrity Amusement Team Ltd. in Sydney, Australia … [+] 14,…

Breaking News
21/05/2025

In Dark K-Drama ‘The Issues’ Disposable Children Should Deal With To Endure

Won Jin-ah plays a return adopter that should conceal to make it through the “problems.” viki.com Tae-Sik, the ruffian in…

Breaking News
23/07/2025

Nvidia reduces Arm risk, buys WeRide, leaves others

Nvidia left settings at numerous firms, consisting of Serve Robotics, Soundhound AI and Nano-X imaging.

Tech
03/04/2025

BYD’s Wang Chuanfu Acquired $9 Billion By Defeating Tesla In Global Sales

On March 24, the day the firm introduced document earnings, BYD stands at an exhibit kept in Hangzhou. CFOTO/Future Posting…

Breaking News
19/07/2025

Asia Tech Times (ISSN: 3079-8566) stands as a preeminent authority in technology journalism, delivering profound insights and strategic intelligence on the technological advancements shaping the Asia-Pacific region and beyond. Renowned for its depth of analysis and editorial excellence, the publication serves as a critical nexus for industry leaders, policymakers, scholars, and innovators navigating the evolving digital landscape.

  • Jobs Board
  • About Us
  • Contact Us
  • Privacy Policy
  • Exclusives
  • Learn How
  • Support
  • Solutions
  • Terms And Conditions
  • Editorial Policy
  • Marketing Solutions
  • Industry Intelligence

Follow US: 

Copyright © 2025 Asia Tech Times. All Rights Reserved.

All content published by Asia Tech Times (ISSN: 3079-8566), including but not limited to articles, reports, editorials, graphics, images, logos, and digital media, is the exclusive intellectual property of Asia Tech Times and is protected under international copyright laws and treaties.

Asia Tech TimesAsia Tech Times
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?